Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Evaluation of cytokine responses against novel Mtb antigens as diagnostic markers for TB disease.

Awoniyi DO, Teuchert A, Sutherland JS, Mayanja-Kizza H, Howe R, Mihret A, Loxton AG, Sheehama J, Kassa D, Crampin AC, Dockrell HM, Kidd M, Rosenkrands I, Geluk A, Ottenhoff TH, Corstjens PL, Chegou NN, Walzl G; AE-TBC Consortium..

J Infect. 2016 Sep;73(3):219-30. doi: 10.1016/j.jinf.2016.04.036. Epub 2016 Jun 14.

PMID:
27311746
2.

Diagnostic performance of a seven-marker serum protein biosignature for the diagnosis of active TB disease in African primary healthcare clinic attendees with signs and symptoms suggestive of TB.

Chegou NN, Sutherland JS, Malherbe S, Crampin AC, Corstjens PL, Geluk A, Mayanja-Kizza H, Loxton AG, van der Spuy G, Stanley K, Kotzé LA, van der Vyver M, Rosenkrands I, Kidd M, van Helden PD, Dockrell HM, Ottenhoff TH, Kaufmann SH, Walzl G; AE-TBC consortium..

Thorax. 2016 Sep;71(9):785-94. doi: 10.1136/thoraxjnl-2015-207999. Epub 2016 May 4.

PMID:
27146200
3.

Multi-center evaluation of a user-friendly lateral flow assay to determine IP-10 and CCL4 levels in blood of TB and non-TB cases in Africa.

Corstjens PL, Tjon Kon Fat EM, de Dood CJ, van der Ploeg-van Schip JJ, Franken KL, Chegou NN, Sutherland JS, Howe R, Mihret A, Kassa D, van der Vyver M, Sheehama J, Simukonda F, Mayanja-Kizza H, Ottenhoff TH, Walzl G, Geluk A; AE-TBC consortium..

Clin Biochem. 2016 Jan;49(1-2):22-31. doi: 10.1016/j.clinbiochem.2015.08.013.

PMID:
26285074
4.

Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium.

Dorman SE, Goldberg S, Stout JE, Muzanyi G, Johnson JL, Weiner M, Bozeman L, Heilig CM, Feng PJ, Moro R, Narita M, Nahid P, Ray S, Bates E, Haile B, Nuermberger EL, Vernon A, Schluger NW; Tuberculosis Trials Consortium..

J Infect Dis. 2012 Oct 1;206(7):1030-40.

PMID:
22850121
5.

Anti-phospholipid antibody levels as biomarker for monitoring tuberculosis treatment response.

Goodridge A, Cueva C, Lahiff M, Muzanye G, Johnson JL, Nahid P, Riley LW.

Tuberculosis (Edinb). 2012 May;92(3):243-7. doi: 10.1016/j.tube.2012.02.004.

6.

Effect of HIV infection on tolerability and bacteriologic outcomes of tuberculosis treatment.

Bliven-Sizemore EE, Johnson JL, Goldberg S, Burman WJ, Villarino ME, Chaisson RE; Tuberculosis Clinical Trials Consortium..

Int J Tuberc Lung Dis. 2012 Apr;16(4):473-9. doi: 10.5588/ijtld.11.0548.

PMID:
22325844
7.

Geographic differences in time to culture conversion in liquid media: Tuberculosis Trials Consortium study 28. Culture conversion is delayed in Africa.

Mac Kenzie WR, Heilig CM, Bozeman L, Johnson JL, Muzanye G, Dunbar D, Jost KC Jr, Diem L, Metchock B, Eisenach K, Dorman S, Goldberg S.

PLoS One. 2011 Apr 11;6(4):e18358. doi: 10.1371/journal.pone.0018358.

8.

Evaluation of time to detection of Mycobacterium tuberculosis in broth culture as a determinant for end points in treatment trials.

Weiner M, Prihoda TJ, Burman W, Johnson JL, Goldberg S, Padayatchi N, Duran P, Engle M, Muzanye G, Mugerwa RD, Sturm AW.

J Clin Microbiol. 2010 Dec;48(12):4370-6. doi: 10.1128/JCM.00757-10.

9.

Impact of mouth rinsing before sputum collection on culture contamination.

Muzanye G, Morgan K, Johnson J, Mayanja-Kizza H.

Afr Health Sci. 2009 Sep;9(3):200. No abstract available.

10.

Influence of M. tuberculosis lineage variability within a clinical trial for pulmonary tuberculosis.

Nahid P, Bliven EE, Kim EY, Mac Kenzie WR, Stout JE, Diem L, Johnson JL, Gagneux S, Hopewell PC, Kato-Maeda M; Tuberculosis Trials Consortium..

PLoS One. 2010 May 20;5(5):e10753. doi: 10.1371/journal.pone.0010753.

11.

Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.

Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, Bozeman L, Heilig CM, Bernardo J, Choudhri S, Grosset JH, Guy E, Guyadeen P, Leus MC, Maltas G, Menzies D, Nuermberger EL, Villarino M, Vernon A, Chaisson RE; Tuberculosis Trials Consortium..

Am J Respir Crit Care Med. 2009 Aug 1;180(3):273-80. doi: 10.1164/rccm.200901-0078OC.

PMID:
19406981
12.

Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis.

Burman WJ, Goldberg S, Johnson JL, Muzanye G, Engle M, Mosher AW, Choudhri S, Daley CL, Munsiff SS, Zhao Z, Vernon A, Chaisson RE.

Am J Respir Crit Care Med. 2006 Aug 1;174(3):331-8.

PMID:
16675781

Supplemental Content

Loading ...
Support Center